Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
"There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use," said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognize
Share
Key Phase 2 Results
Primary Endpoint Achieved: Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia compared to vehicle at Day 28, as assessed by an independent reading center using digital imaging.
Rapid Onset and Sustained Efficacy: Significant improvements were observed as early as Day 7 with the highest investigated concentration CBT-004 , with benefits persisting through the 28-day treatment period.
Significant Symptom Relief: Both CBT-004 concentrations showed statistically significant improvements in five common patient-reported symptoms including burning/stinging, itching, foreign body sensation, eye discomfort, and pain compared to vehicle.
Excellent Safety Profile: No treatment-related adverse events were observed. Most adverse events were mild to moderate. No clinically meaningful changes in visual acuity or intraocular pressure were reported.
Addressing a Significant Unmet Medical Need
Vascularized pinguecula affects millions of Americans and represents a substantial unmet medical need in ophthalmology. This common, benign conjunctival growth can become problematic when it develops abnormal blood vessels and inflammation, which can lead to persistent redness, irritation, pain, and foreign body sensation. Current management options are limited, with many patients relying on off-label corticosteroids or surgical excision, both of which carry significant limitations and potential complications.
Study Design and Results
The multicenter, randomized, double-masked, vehicle-controlled Phase 2 study enrolled 88 adult patients with vascularized pinguecula and associated conjunctival hyperemia. Participants were randomized to receive one of two concentrations of CBT-004, or vehicle. The primary endpoint was the change from baseline in conjunctival hyperemia at Day 28, as measured by an independent reading center using standardized digital imaging protocols.
Expert Commentary
"There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use," said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognized key opinion leader in anterior segment disease. "The results from this trial are exciting, as they demonstrate that a targeted, non- steroidal therapy can meaningfully improve both the clinical signs and symptoms that impact patients' quality of life."
"As a principal investigator in this study, I was impressed by the consistency and magnitude of improvement in both objective redness and patient-reported discomfort with CBT-004," commented Dr. Sherif El-Harazi, Medical Director at Global Research Management. "The safety profile was excellent, and I believe this therapy could represent a meaningful advance for our patients with vascularized pinguecula."
About CBT-004
CBT-004 is a novel, preservative-free topical ophthalmic solution containing a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors and platelet-derived growth factor (PDGF) receptors. The formulation is specifically designed to reduce abnormal blood vessel growth and inflammation associated with vascularized pinguecula while minimizing potential ocular surface toxicity through its preservative- free composition.
Next Steps and Regulatory Strategy
Based on these positive Phase 2 results, Cloudbreak Pharma Inc. plans to advance CBT-004 into Phase 3 development and initiate discussions with the U.S. Food and Drug Administration (FDA) to establish the regulatory pathway toward potential approval. The company anticipates providing updates on Phase 3 study design and timing in the coming months.
Market Opportunity
The vascularized pinguecula market represents a significant commercial opportunity with limited therapeutic options. The prevalence of pinguecula increases with age and UV exposure, affecting a substantial portion of the aging population. With no FDA-approved treatments specifically indicated for this condition, CBT-004 has the potential to become a category-defining therapy in this underserved market.
About Cloudbreak Pharma Inc.
Cloudbreak Pharma Inc. is a clinical-stage ophthalmology company dedicated to developing innovative therapies for ocular surface diseases with high unmet medical need. The company's pipeline focuses on novel treatments targeting inflammation, vascularization, and other pathological processes affecting the ocular surface. Cloudbreak is committed to improving outcomes for patients with challenging eye conditions through scientifically-driven therapeutic development.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential therapeutic benefits of CBT-004, the company's clinical development plans, regulatory strategy, and market opportunity. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause actual results to differ include, but are not limited to, the uncertainty of clinical trial results, regulatory approval processes, competitive developments, and other risks detailed in the company's filings. The company undertakes no obligation to update these forward-looking statements except as required by law.
Please note that the information contained in this press release may not be complete. For further details about Cloudbreak Pharma Inc., and our drug candidates, please refer to our company's website (at www.cloudbreakpharma.com).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
32 minutes ago
- Business Wire
Earnings Teleconference Moves to Earlier Time on July 29
--(BUSINESS WIRE)--As previously announced, UnitedHealth Group will release its second quarter 2025 financial results on Tuesday, July 29, 2025, before the market opens. The start time for the teleconference has moved to 8:00 a.m. ET, 45 minutes earlier than previously announced, to allow more time for discussion of results with analysts and investors. This call will be webcast on the Investor Relations page of the company's website ( The replay will be available through August 12 on the website. UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn.
Boston Globe
32 minutes ago
- Boston Globe
US and Mexico sign deal to stop sewage release into Tijuana River
Lee Zeldin, the administrator of the Environmental Protection Agency, who traveled to Mexico to sign the memorandum of understanding with Alicia Bárcena Ibarra, Mexico's environment secretary, wrote in a statement that the countries are aiming for a 'permanent, 100% solution.' Under the deal, Mexico agreed to complete an allocation of $93 million toward sanitation infrastructure, and complete all projects by Dec. 31, 2027, the EPA said. The United States, which had withheld funds for water infrastructure improvements on the border, will release money to complete the rehabilitation of a pump station and other projects. Advertisement 'The Trump administration is proud to deliver this massive environmental and national security win for Americans in the San Diego area who have been living with this disgusting raw sewage flowing into their communities for far too long,' Zeldin said in a statement. Advertisement Bárcena Ibarra said in a statement the agreement 'strengthens collaboration to address environmental and health challenges along the northern border.' San Diego County residents have suffered acutely. The Office of the Naval Inspector General this year found that more than 1,100 Navy recruits contracted gastrointestinal illnesses after training in southern San Diego waters. And nearly half of the 40,900 households in the region have experienced health problems, including rashes and shortness of breath, that were most likely attributable to the sewage, according to the US Centers for Disease Control and Prevention. The agreement comes three months after Zeldin visited San Diego to begin negotiations with Mexico. It drew praise from local officials, including from Democrats, but some environmental advocates said more needs to be done. Jim Desmond, a Republican supervisor of the San Diego County Board of Supervisors, wrote on the social platform X that the announcement 'marks a significant step forward.' He said the federal government had previously failed to hold Mexico accountable for the sewage flowing into California. 'Our beaches must be clean, safe, and open year-round — anything less is unacceptable,' he wrote. Todd Gloria, the mayor of San Diego and a Democrat, thanked Zeldin on X and called the deal 'a huge step toward ending this crisis.' Matthew Tejada, senior vice president of environmental health for the Natural Resources Defense Council, an environmental group, called the agreement a good start. 'It's great that we're starting to roll up our sleeves' on this issue, he said. But he added that the waste-water improvements are enormous and complicated infrastructure projects that are likely going to be hit with unexpected problems, including worsening levels of runoff and sewage exacerbated by climate-fueled storms. 'These are really tough projects to implement, with really elusive outcomes,' he said. Advertisement This article originally appeared in
Los Angeles Times
2 hours ago
- Los Angeles Times
Criminalization or support? President Trump's executive order on homelessness gets mixed reaction
An executive order signed by President Trump purporting to protect Americans from 'endemic vagrancy, disorderly behavior, sudden confrontations, and violent attacks' attributed to homelessness has left local officials and homeless advocates outraged over its harsh tone while also grasping for a hopeful message in its fine print. The order Trump signed Thursday would require federal agencies to reverse precedents or consent decrees that impede U.S. policy 'encouraging civil commitment of individuals with mental illness who pose risks to themselves or the public or are living on the streets and cannot care for themselves.' It ordered those agencies to 'ensure the availability of funds to support encampment removal efforts.' Depending on how that edict is carried out, it could extend a lifeline for Mayor Karen Bass' Inside Safe program, which has eliminated dozens of the city's most notable encampments but faces budget challenges to maintain the hotel and motel beds that allow people to move indoors. Responding to the order Friday, Bass said she was troubled that it called for ending street homelessness and moving people into rehabilitation facilities at the same time as the administration's cuts to Medicaid have affected funding 'streams for facilities for people to stay in, especially people who are disabled.' 'Of course I'm concerned about any punitive measures,' Bass said. 'But first and foremost, if you want to end street homelessness, then you have got to have housing and services for people who are on the street.' Kevin Murray, president and chief executive of the Weingart Center homeless services and housing agency, saw ambiguity in the language. 'I couldn't tell whether he is offering money for people who want to do it his way or taking money away from people who don't do it his way,' Murray said. Others took their cue from the order's provocative tone set in a preamble declaring that the overwhelming majority of the 274,224 people reported living on the street in 2024 'are addicted to drugs, have a mental health condition, or both.' The order contradicted a growing body of research finding that substance use and mental illness, while significant, are not overriding factors in homelessness. 'Nearly two-thirds of homeless individuals report having regularly used hard drugs like methamphetamines, cocaine, or opioids in their lifetimes. An equally large share of homeless individuals reported suffering from mental health conditions.' A February study by the Benioff Homeless and Housing Initiative at UC San Francisco found that only about 37% of more than 3,000 homeless people surveyed in California were using illicit drugs regularly, but just over 65% reported having regularly used at some point in their lives. More than a third said their drug use had decreased after they became homeless and one in five interviewed in depth said they were seeking treatment but couldn't get it. 'As with most executive orders, it doesn't have much effect on its own,' said Steve Berg, chief policy officer for the National Alliance to End Homelessness. 'It tells the federal agencies to do different things. Depending on how the federal agencies do those things, that's what will have the impact.' In concrete terms, the order seeks to divert funding from two pillars of mainstream homelessness practice, 'housing first,' the prioritization of permanent housing over temporary shelter, and 'harm reduction,' the rejection of abstinence as a condition of receiving services and housing. According to the order, grants issued under the Substance Abuse and Mental Health Services Administration should 'not fund programs that fail to achieve adequate outcomes, including so-called 'harm reduction' or 'safe consumption' efforts that only facilitate illegal drug use and its attendant harm.' And the Secretary of Health and Human Services and the Secretary of Housing and Urban Development should, to the extent permitted by law, end support for 'housing first' policies that 'deprioritize accountability and fail to promote treatment, recovery, and self-sufficiency.' To some extent, those themes reflect shifts that have been underway in the state and local response to homelessness. Under pressure from Gov. Gavin Newsom, the California legislature established rules allowing relatives and service providers to refer people to court for treatment and expanded the definition of gravely disabled to include substance use. Locally, Bass' Inside Safe program and the county's counterpart, Pathway Home, have prioritized expanding interim housing to get people off the streets immediately. Trump's order goes farther, though, wading into the controversial issue of how much coercion is justified in eliminating encampments. The Attorney General and the other federal agencies, it said, should take steps to ensure that grants go to states and cities that enforce prohibitions on open illicit drug use, urban camping and loitering and squatting. Homeless advocacy organizations saw those edicts as a push for criminalization of homelessness and mental illness. 'We'll be back to the days of 'One Flew Over the Cuckcoo's Nest,' 'Berg said, referring to the 1962 novel and subsequent movie dramatizing oppressive conditions in mental health institutions. Defending Housing First as a proven strategy that is the most cost-effective way to get people off the street, Berg said the order encourages agencies to use the money in less cost-effective ways. 'What we want to do is reduce homelessness,' he said. 'I'm not sure that is the goal of the Trump administration.' The National Homelessness Law Center said in a statement saying, 'This Executive Order is rooted in outdated, racist myths about homelessness and will undoubtedly make homelessness worse.... Trump's actions will force more people into homelessness, divert taxpayer money away from people in need, and make it harder for local communities to solve homelessness.' Murray, who describes himself as not a fan of Housing First, noted that key policies pressed in the order—civil commitment, encampment removal and substance use treatment—are already gaining prominence in the state and local response to homelessness. 'We all think if it came from Trump it is horrible,' Murray said. 'It is certainly overbearing. It certainly misses some nuances of what real people with mental illness and substance use are like. But we've started down the path of most of this stuff.' His main concern was that the order might be interpreted to apply to Section 8, the primary federal financial tool for getting homeless people into housing. What would happen, he asked, if someone with a voucher refused treatment? 'It might encourage more people to stay on the streets,' he said. 'Getting people into treatment isn't easy.'
